NICE CITES HIGH COSTS AND MODEST BENEFITS IN HISTORIC DECISION
The National Institute for Health and Care Excellence (NICE) has ruled that two groundbreaking Alzheimer’s drugs, donanemab and lecanemab, are too expensive for the National Health Service (NHS) in England to fund. Despite marking a significant scientific advance in slowing Alzheimer’s disease progression, NICE concluded that the high price and limited clinical benefit make […]